Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
Recent advances in the development of therapeutic antibodies (Abs) have greatly improved the treatment of otherwise drug-resistant cancers and autoimmune diseases. Antibody activities are mediated by both their Fab and the Fc. However, therapeutic Abs base their protective mechanisms on Fc-mediated...
Main Authors: | Andréa Cottignies-Calamarte, Daniela Tudor, Morgane Bomsel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1037033/full |
Similar Items
-
Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants
by: Robert Pejchal, et al.
Published: (2023-08-01) -
IgG Fc engineering to modulate antibody effector functions
by: Xinhua Wang, et al.
Published: (2017-10-01) -
Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
by: Yvonne J. Rosenberg, et al.
Published: (2023-04-01) -
Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
by: Gilles Thibault, et al.
Published: (2021-06-01) -
Impact of structural modifications of IgG antibodies on effector functions
by: Timon Damelang, et al.
Published: (2024-01-01)